Condition: Exudative Age-Related Macular Degeneration · Sponsor: Nantes University Hospital
Age-related macular degeneration is a leading cause of visual impairment in older adults. In its exudative form, repeated intravitreal injections of anti-VEGF agents are required to control disease activity. A new formulation of aflibercept at a higher dose (8 mg) has been developed with the aim of extending the interval between injections. This multicenter retrospective real-world observational study will evaluate the effect of switching to aflibercept 8 mg in patients with refractory or dependent exudative age-related macular degeneration. Clinical data collected during routine care will be analyzed to compare injection intervals, treatment burden, visual outcomes, anatomical outcomes, and safety before and after the switch.
This description comes directly from the study's public registry record.
Jean Baptiste DUCLOYER, MD, PhD · 02 40 08 34 01 · jeanbaptiste.ducloyer@chu-nantes.fr
Alexandra Poinas, PhD · +33 2 53 48 28 57 · alexandra.poinas@chu-nantes.fr
Always discuss trial participation with your own doctor first.
| CHU Nantes - Ophthalmology Department | Nantes, Nantes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07423429